Sanj Patel is Chief Executive Officer and Chairman of the Board of Kiniksa Pharmaceuticals International, plc (KNSA). The company reported total compensation of $10,782,661 for fiscal year 2025.
| Salary | $943,129 |
|---|---|
| Bonus | $3,798,021 |
| Stock awards | $4,743,446 |
| Option awards | $1,284,065 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $14,000 |
| Total | $10,782,661 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Kiniksa Pharmaceuticals International, plc filed April 16, 2026, accession 0001104659-26-044410.
| Peer-group chief executive median | $8,526,943 |
|---|---|
| Difference from that median | $2,255,718 |
| Percentile within the disclosed peer group | 53rd |
| Peers with a disclosed figure | 15 |
Medians and percentiles are computed across the peer group Kiniksa Pharmaceuticals International, plc discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Sanj Patel this page | Chief Executive Officer and Chairman of the Board | $10,782,661 |
| Ross Moat | Executive Vice President and Chief Operating Officer | $3,638,001 |
| John Paolini | Executive Vice President and Chief Medical Officer | $3,570,655 |
| Eben Tessari | Executive Vice President and Chief Strategy Officer | $3,566,231 |
| Mark Ragosa | Executive Vice President and Chief Financial Officer | $3,283,055 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Kiniksa Pharmaceuticals International, plc compensation brief.
Sanj Patel's compensation sits inside Kiniksa Pharmaceuticals International, plc's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.
The Kiniksa Pharmaceuticals International, plc (KNSA) compensation brief